Acute Exfoliative Dermatitis/Erythroderma Secondary to Gliclazide.
dermatitis
erythroderma
exfoliative
gliclazide
skin rash
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
Sep 2023
Sep 2023
Historique:
accepted:
25
09
2023
medline:
28
9
2023
pubmed:
28
9
2023
entrez:
28
9
2023
Statut:
epublish
Résumé
Erythroderma is a general term used to describe severe, intense skin inflammation. The condition is also known as exfoliative dermatitis when it is associated with exfoliation. Erythroderma has many causes, such as adverse drug eruption, dermatitis, psoriasis, pityriasis rubra pilaris, immunobullous disease, cutaneous T-cell lymphoma (Sézary syndrome), underlying systemic malignancy, graft versus host disease, and HIV infection. Many medications can cause erythroderma, including antibiotics, antiepileptics, angiotensin-converting enzyme (ACE) inhibitors, and sulfonamides. Here, we report a rare case of erythroderma secondary to gliclazide, an oral antidiabetic. This presentation is rare, as we found only one case report of gliclazide causing erythroderma in the literature. Erythroderma is considered a medical emergency requiring immediate diagnosis and prompt management; therefore, early intervention should start on suspicion without waiting for dermatologist confirmation, as this will significantly reduce the mortality and morbidity of this potentially life-threatening emergency.
Identifiants
pubmed: 37766779
doi: 10.7759/cureus.45965
pmc: PMC10522441
doi:
Types de publication
Case Reports
Langues
eng
Pagination
e45965Informations de copyright
Copyright © 2023, Al-Badawi et al.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Adv Skin Wound Care. 2015 May;28(5):228-36; quiz 237-8
pubmed: 25882661
Eur J Case Rep Intern Med. 2019 May 29;6(6):001119
pubmed: 31293993